Literature DB >> 17033176

Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis.

Fanny Mougel1, Stéphane Dalle, Brigitte Balme, Roch Houot, Luc Thomas.   

Abstract

Atopic dermatitis (AD) is not regarded as a predisposing condition for cutaneous T cell lymphoma. Cyclosporine (CsA) is an efficient therapy in AD, and its side effects, including lymphocytic proliferation, are rare at the low dose used in such cases. So far 3 cases of patients who developed cutaneous T cell lymphoma under CsA treatment for atopy have been described. An adult patient with a history of AD received CsA therapy because of an atypical flare-up of his eruption. He rapidly developed papular atypical lesions, then followed by the onset of a voluminous cutaneous tumor leading to the diagnosis of mycosis fungoides (MF) transformed in CD30+ large cell lymphoma with nodal and blood involvement. No improvement occurred after withdrawing of CsA, and he required a polychemotherapy and an allograft. This case illustrates the dramatic evolution of an MF under CsA given in the hypothesis of AD. It stresses the fact that skin biopsies should be taken in case of atypical AD to rule out MF and avoid such an aggressive evolution under immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033176     DOI: 10.1159/000095044

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.

Authors:  Maria Estela Martinez-Escala; Alba L Posligua; Heather Wickless; Audrey Rutherford; Kimberly A Sable; Belen Rubio-Gonzalez; Xiaolong A Zhou; Jason B Kaplan; Barbara Pro; Jaehyuk Choi; Christiane Querfeld; Steven T Rosen; Joan Guitart
Journal:  J Am Acad Dermatol       Date:  2018-01-04       Impact factor: 11.527

2.  Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy.

Authors:  Masahiro Ohara; Kokoro Ozaki; Takuya Ohkubo; Akane Yamada; Yoshiyuki Numasawa; Keisuke Tanaka; Shohei Tomii; Satoru Ishibashi; Nobuo Sanjo; Takanori Yokota
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.